Effect of Glucose on Ocular Blood Flow

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Completed
CT.gov ID
NCT00350129
Collaborator
(none)
24
1
2
11.8

Study Details

Study Description

Brief Summary

The primary objective is to assess the effect of glucose on retinal vascular diameter in otherwise healthy vasospastic subjects compared to non-vasospastic controls.

The secondary objective is to compare the effect of glucose also on choroidal blood flow in otherwise healthy vasospastic subjects with non-vasospastic controls.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    It is known that a glucose load can induce an increase in ocular blood flow. Acute hyperglycemia increases retinal vessel diameters in animals and humans. The purpose of this study is to compare the effect of glucose on the ocular blood flow in vasospastics and nonvasospastics. Body core temperature depends on basal metabolism. Peripheral vasoconstriction is a physiological way to preserve core temperature of the body. The etiology of primary vasospastic syndrome is unknown and potentially represents simply a reaction to a defective metabolism. Based on this hypothesis, vasospastics are expected to show a different vascular reaction to glucose.

    On both study days, after an overnight fast, the subjects will be seated for 30 minutes in the Lab and local tropicamide will be applied for pupil dilatation. After stabilisation of blood pressure Retinal vessel diameter and choroidal blood flow will be assessed. Baseline blood glucose levels will be measured. Afterwards study substance (75 gram of Glucose or Aspartate) will be applied in 3 dl of water. One and a half hour later, the vascular measurements will be repeated. Ath the end of hemodynamic assessments, blood sugar level will be measured again.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    24 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Influence of Plasma Glucose Levels on Retinal Vascular Diameter and Choroidal Blood Flow in Vasospastic Subjects
    Study Start Date :
    Dec 1, 2002
    Actual Primary Completion Date :
    Feb 1, 2003
    Actual Study Completion Date :
    Feb 1, 2003

    Arms and Interventions

    Arm Intervention/Treatment
    1

    healthy vasospastic subjects

    2

    healthy non-vasospastic subjects

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 85 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:
      • No history of the following problems: ocular or systemic disease; chronic or current systemic or topical medication; or of drug or alcohol abuse

      • normal blood pressure (100-140 / 60-90 mmhg)

      • best corrected visual acuity above 20/25 in both eyes

      • no pathological findings upon a slit-lamp examination and indirect fundoscopy

      • ametropia within -3 to +3 diopters of spherical equivalent

      • less than 1 diopter astigmatism

      • IOP < 20 mmHg in both eyes

      • Subjects will be classified as vasospastic if they relate a clear history of frequent cold hands (answering yes to the questions: "do you have always cold hands, even during summer time?" and "do other people tell you that you have cold hands?") and as normals if they deny such a history

      • Vasospastic propensity will also be assessed by capillaroscopy

      Exclusion Criteria:
      • Subjects describing "sometimes cold hands"

      • if the test substance cannot be ingested

      • not obtainable ocular blood flow measurements

      • abnormally high levels of glucose at any point in time

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 University Hospital Basel, Eye Clinic Basel BS Switzerland 4031

      Sponsors and Collaborators

      • University Hospital, Basel, Switzerland

      Investigators

      • Study Director: Selim Orgül, MD, University Hospital, Basel, Switzerland

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00350129
      Other Study ID Numbers:
      • 005-ZAC-2004-002
      First Posted:
      Jul 10, 2006
      Last Update Posted:
      Sep 26, 2008
      Last Verified:
      Sep 1, 2008
      Keywords provided by , ,
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Sep 26, 2008